BioHarvest Sciences (NASDAQ:BHST) Earns Buy Rating from Analysts at HC Wainwright

HC Wainwright began coverage on shares of BioHarvest Sciences (NASDAQ:BHST) in a report issued on Friday morning, MarketBeat.com reports. The firm issued a buy rating and a $14.00 price target on the stock.

BioHarvest Sciences Trading Up 1.3 %

NASDAQ:BHST opened at $6.05 on Friday. BioHarvest Sciences has a fifty-two week low of $6.04 and a fifty-two week high of $7.70. The stock has a market cap of $99.34 million and a PE ratio of -4.84.

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.